1. Identification
Catalogue code: H0200000  Unit Quantity*: ca 1.1 mL

* Please note that the total amount of material (active substance and excipients, if any) which has been filled in each vial or ampoule, for customs purposes only. Circa (“ca”) quantity is not to be considered accurate from an analytical point of view.

2. Scientific Information
2.1 Intended use
Heparin sodium BRP batch 4 consists of a liquid heparin sodium preparation in ampoules. It was established for use in the assay of unfractionated heparin according to the Ph. Eur. General text 2.7.5. with assigned contents of 985 IU/mL for anti-IIa and 995 IU/mL for anti-Xa activities.

When used in the test for heparin in human antithrombin III according to the Ph. Eur. Monograph 0878, Heparin sodium BRP has an assigned content of 1035 IU/mL for sheep plasma clotting assay.

Heparin sodium BRP batch 4 may also be used in the assay of protamine sulfate according to the prescriptions of the Ph. Eur. Monograph 0569.

2.2 Instructions for use
• Open the ampoule by mechanical action, taking care that no glass falls into the ampoule.
• Extract the desired volume of solution and use as soon as possible after opening.

2.3 The Uncertainty of the assigned value
The uncertainty of the assigned value is not stated since it is considered to be negligible in relation to the defined limits of the method-specific assays for which the reference standard is used. Please also refer to Ph. Eur. chapter 5.12.

2.4 Validity
A statement on the validity of the batch (Batch Validity Statement) can be printed directly from the EDQM website (Reference Standards Database).

3. Storage conditions
Store the original container at +5°C ± 3°C. Once opened, the ampoule is for immediate use and the stability of the contents of opened ampoules cannot be guaranteed.

4. Safety
Biological preparation for laboratory use only. Handle in accordance with good occupational hygiene, safety and laboratory practices and take precautions to avoid exposure.

5. Shipping conditions
Please check shipping conditions on the EDQM website (Reference Standards Database).

6. Additional information
Pharmeur Bio Sci Notes is an open-access publication that is freely available on the EDQM website (www.edqm.eu). EDQM website (Knowledge Database, Reference Standards Database, HelpDesk).

7. **Citation**

Users shall ensure that any reference made to an EDQM Reference Standard in any publication, presentation or public document (e.g. scientific articles, data sheets for kits) bears the exact name, and catalogue code of the Reference Standard and the exact name and address of EDQM as given on the first page of this information leaflet.

8. **Warranties, Liability and disputes**

   a) **Warranties**

   The Council of Europe does not offer any warranty concerning the quality or safety of any item supplied, the absence of any defects, or its fitness for any particular purpose except that of use as a Ph. Eur. CRS, BRP or RS for use as reference standards in tests and assays carried out in accordance with the official methods of the European Pharmacopoeia (Ph. Eur.) by professionals with the necessary technical skills. In particular, the Council of Europe (EDQM) does not guarantee that the items will meet the customer’s specific expectations. The Council of Europe also does not guarantee that the purchase or use of the items will not infringe any intellectual property rights, in particular patents.

   The Council of Europe (EDQM) only guarantees that the items meet the above conditions in the moment they are handed over to the carrier being responsible for the delivery of the item to the purchaser and that the carrier and the purchaser have received clear and accurate instructions for the item’s delivery and reception.

   No other warranty, either express or implied, is given by the Council of Europe (EDQM).

   b) **Liability**

   The Council of Europe (EDQM) shall not be liable for the failure to meet the requirements of the legislation of the country where the items are delivered. It is the purchaser’s responsibility to check with the local, regional or national authorities and to make sure that the goods or services that they intend to order may be imported or used in that country. The purchaser is solely responsible for the choice of items, their storage from the time of delivery and their use.

   In no event shall the Council of Europe (EDQM) be liable for any damages due to the use of items, including, but not limited to, lost profits, loss of use, costs of procurement of substitute goods, services or systems, or for any indirect, special, incidental, punitive, or consequential damages, however caused and, whether in contract, tort or under any other theory of liability, whether or not the Purchaser has been advised of the possibility of such damage.

   c) **Disputes**

   In accordance with the provisions of article 21 of the General Agreement on the Privileges and Immunities of the Council of Europe, all disputes between the Council of Europe (EDQM) and the customer as regards the application of this contract shall be submitted, if a mutual agreement cannot be reached between the parties, to arbitration as laid down in Order No. 481 of the Secretary General, approved by the Committee of Ministers.

9. **Adoption**

   The present reference standard has been officially adopted by the European Pharmacopoeia Commission.

10. **Signature**

    This document is electronically signed by:

    **Dr Pierre Leveau**

    **Head of the Quality, Safety and Environment Division**